JCI The Journal of Clinical Investigation

Tim-3 expression on PD-1$^+$ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity

Rachel H. McMahan, … , David R. Gretch, Hugo R. Rosen

J Clin Invest. 2011;121(2):821-821. https://doi.org/10.1172/JCI46311.

Corrigendum

Original citation: J. Clin. Invest. 2010;120(12):4546–4557. doi:10.1172/JCI43127. Citation for this corrigendum: J. Clin. Invest. 2011;121(2):821. doi:10.1172/JCI46311. In the section of Methods titled “Antibodies and flow cytometric analysis,” the antibody clone name for the anti–Tim-3 antibody was given incorrectly. The correct sentences appear below: Directly conjugated antibodies against the following surface molecules were used: CCR7–PE-Cy7 (clone 3D12), CD27–APC-H7 (clone M-T271), CD45RA-APC (clone HI100), CD69-FITC (clone L78), HLA-DR–PerCP (clone L243), CD45RO–PE-Cy7 (clone UCHL1), CD3–Pacific Blue (clone UCHT1), CD4-V500 (clone RPA-T4), CD8–Alexa Fluor 700 or CD8-PerCP (clone SK1), and PD-1–FITC (clone MIH4), all from BD Biosciences. The PE-conjugated antibody and the blocking antibody for Tim-3 (clone 344823) were obtained from R&D; the blocking antibody gave results that were comparable to those of 1G5 anti–Tim-3 antibody, provided by Vijay Kuchroo (Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA). The authors regret the error.

Corrigendum

Tim-3 expression on PD-1$^+$ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity

Rachel H. McMahan, Lucy Golden-Mason, Michael I. Nishimura, Brian J. McMahon, Michael Kemper, Todd M. Allen, David R. Gretch, and Hugo R. Rosen

Original citation: *J Clin Invest.* 2010;120(12):4546–4557. doi:10.1172/JCI43127.

Citation for this corrigendum: *J Clin Invest.* 2011;121(2):821. doi:10.1172/JCI46311.

In the section of Methods titled "Antibodies and flow cytometric analysis," the antibody clone name for the anti–Tim-3 antibody was given incorrectly. The correct sentences appear below:

Directly conjugated antibodies against the following surface molecules were used: CCR7–PE-Cy7 (clone 3D12), CD27–APC-H7 (clone M-T271), CD45RA-APC (clone HI100), CD69-FITC (clone L78), HLA-DR–PerCP (clone L243), CD45RO–PE-Cy7 (clone UCHL1), CD3–Pacific Blue (clone UCHT1), CD4-V500 (clone RPA-T4), CD8–Alexa Fluor 700 or CD8-PerCP (clone SK1), and PD-1–FITC (clone MIH4), all from BD Biosciences. The PE-conjugated antibody and the blocking antibody for Tim-3 (clone 344823) were obtained from R&D; the blocking antibody gave results that were comparable to those of 1G5 anti–Tim-3 antibody, provided by Vijay Kuchroo (Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA).

The authors regret the error.

Clarification

***PDZD7* is a modifier of retinal disease and a contributor to digenic Usher syndrome**

Inga Ebermann, Jennifer B. Phillips, Max C. Liebau, Robert K. Koenekoop, Bernhard Schermer, Irma Lopez, Ellen Schäfer, Anne-Francoise Roux, Claudia Dafinger, Antje Bernd, Eberhart Zrenner, Mireille Claustres, Bernardo Blanco, Gudrun Nürnberg, Peter Nürnberg, Rebecca Ruland, Monte Westerfield, Thomas Benzing, and Hanno J. Bolz

Original citation: *J Clin Invest.* 2010;120(6):1812–1823. doi:10.1172/JCI39715.

Citation for this clarification: *J Clin Invest.* 2011;121(2):821. doi:10.1172/JCI46312.

Since the article was published, the zebrafish genome assembly has been updated from zv8 to zv9, and the exon numbers have changed. The *ush2a* GT sequence (5′-GTACGACCTTATGCTTACCTGTTGG-3′) was originally thought to target the splice donor site of exon 6, but it has been updated to exon 4 of *ush2a*, as annotated in the Ensembl transcript ID ENSDART00000086201.